Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC-3595 in Subjects With Insulin Resistance
NCT05665751Phase 2Active, not recruiting
- Sponsor
- OrsoBio
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tlc-3595 in insulin resistance (IR) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by OrsoBio. Primary endpoints: Change in insulin sensitivity at Day 84 and Incidence of TLC-3595 treatment-emergent adverse events at Day 84. Started Mar 2023; status: active, not recruiting.
02
Drugs
tlc-3595
03
Conditions
insulin resistance (IR)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05665751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665751.